Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation

European Journal of Neurology

Volumn 18, Issue 12, 2011, Pages 1407-1411

  Brunner, F ^a   Tomandl, B ^a   Schroter A ^a   Mellinghoff, C ^a   Haldenwanger, A ^a   Hildebrandt, H ^a   Kastrup, A ^a  

^a KLINIKUM BREMEN MITTE   (Germany)

Author keywords

Acute cerebral infarction; Anticoagulation; Symptomatic intracerebral hemorrhage; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN;

ACUTE ISCHEMIC STROKE; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN HEMORRHAGIC INFARCT; BRAIN ISCHEMIA; BRAIN PARENCHYMAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; SIDE EFFECT; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; THROMBOCYTE COUNT; TIME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGIC DISORDERS; HOSPITAL MORTALITY; HUMANS; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 81855194288     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03455.x     Document Type: Article

References (21)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
3. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
4. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
5. Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007; 38: 2275-2278.
6. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-1685.
7. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-923.
8. Kim YD, Lee JH, Jung YH, et al. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci 2010; 298: 101-105.
9. Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450-1458.
10. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2010; 67: 559-563.
11. Vergouwen MD, Casaubon LK, Swartz RH, et al. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 2011; 42: 1041-1045.
12. Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-441.
13. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
14. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
15. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000; 283: 1145-1150.
16. Rizos T, Herweh C, Jenetzky E, et al. Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009; 40: 3547-3551.
17. Janjua N, Alkawi A, Georgiadis A, et al. Feasibility of IA thrombolysis for acute ischemic stroke among anticoagulated patients. Neurocrit Care 2007; 7: 152-155.
18. Linfante I, Reddy AS, Andreone V, Caplan LR, Selim M, Hirsch JA. Intra-arterial thrombolysis in patients treated with warfarin. Cerebrovasc Dis 2005; 19: 133-135.
19. Nogueira RG, Smith WS. Safety and efficacy of endovascular thrombectomy in patients with abnormal hemostasis: pooled analysis of the MERCI and multi MERCI trials. Stroke 2009; 40: 516-522.
20. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33: 717-724.
21. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32: 12-16.